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Summary
Hypermethylation of CpG islands in theRASSF1 promoter is
one of the most frequent events identified in human cancer
[1–3]. The epigenetic-driven loss of RASSF1A protein
expression is observed more often in tumors of higher grade
and correlates with a decreased responsiveness to DNA-
damaging therapy [4–6]. Ras association domain-containing
family 1A (RASSF1A) promotes apoptosis by signaling
through the MST2 and LATS1 kinases, leading to stabiliza-
tion of the YAP1/p73 transcriptional complex [7]. Here we
provide evidence for a new pathway linking DNA damage
signaling to RASSF1A via the main sensor of double-strand
breaks in cells, ataxia telangiectasia mutated (ATM). We
show that, upon DNA damage, RASSF1A is phosphorylated
by ATM on Ser131 and is involved in the activation of both
MST2 and LATS1, leading to the stabilization of p73. Further-
more, lung and ovarian tumor cell lines that retain RASSF1A
expression commonly harbor polymorphisms in the region
of Ser131 [8], and our analysis shows that the S131F poly-
morphism conveys resistance to DNA-damaging agents.
Thus, we present a novel DNA damage pathway emanating
from ATM that is frequently disabled in tumors via epigenetic
silencing ofRASSF1 or mutation of an ATM phosphorylation
site.
Results and Discussion
RASSF1A and MST2 Pathway Signaling Is Activated
following DNA Damage
To determine whether the Ras association domain-containing
family 1A (RASSF1A)/MST2 pathway is activated upon DNA
damage, we first addressed whether activation of pathway
signaling could be stimulated in response to double-strand
breaks (DSBs) generated by exposure to ionizing radiation.
In U2OS and HeLa cells (data not shown), both of which retain
RASSF1A expression, MST2 associates with LATS1 within
20–30 min of exposure to ionizing radiation (Figure 1A). In
MCF7 cells, where RASSF1A is undetectable because of
promoter methylation, exogenous expression of FLAG-
RASSF1A enhances the induced binding of MST2 and LATS1
observed following exposure to ionizing radiation (Figure 1B).
RASSF1A and MST2 have previously been described to
respond to receptor signaling events [7, 9, 10]; therefore, we
tested whether the MST2 kinase activity was similarly induced
in response to DNA damage. MST2 immunoprecipitates from
HeLa cells demonstrated an increase in kinase activity in
response to ionizing radiation, whereas knockdown of*Correspondence: eric.oneill@rob.ox.ac.ukRASSF1A by small interfering RNA (siRNA) abrogated any
response of MST2 to DNA damage (Figure 1C). Concomitant
activation of LATS1 kinase was also observed and was depen-
dent on RASSF1A and DNA damage (see Figure S1A available
online). We next examined whether the clonogenic potential of
irradiated tumor cells would be enhanced by removal of the
individual components of this pathway via siRNA. The
surviving fraction is directly proportional to the number of cells
present posttransfection, therefore removing any variation
due to inherent tumor-suppressor capacity unrelated to DNA
damage. HeLa cells ablated of RASSF1A by siRNA and
exposed to a clinically relevant dose of 2 Gy ionizing radiation
that sensitizes xenografts to methylation inhibitors in vivo [6]
had increased colony survival compared to controls (Fig-
ure 1D; Figure S1B). Similarly, removal of MST2 and LATS1
also demonstrated enhanced clonogenic survival in response
to treatment with ionizing radiation compared to the nontar-
geting control (Figure 1D; Figure S1B). Therefore, loss of
RASSF1A (as in RASSF1 methylated tumors) or the down-
stream signaling pathway reduces the ability to respond to
DNA damage signals.
RASSF1A Is Phosphorylated on Ser131
in a DNA Damage-Dependent Manner
We next sought to establish the molecular mechanism as to
how RASSF1A was integrating signals from DSBs to the acti-
vation of MST2. The major kinases (ataxia telangiectasia
mutated [ATM], ATM- and RAD51-related [ATR], and DNA
protein-kinase catalytic subunit [DNA-PKcs]) involved in trans-
mitting signals from DSBs to cell-cycle checkpoints, activation
of DNA repair, and/or apoptosis belong to the phosphoinosi-
tide 3-kinase-related kinase (PIKK) family [11–13]. ATM, ATR,
and DNA-PKcs are Ser/Thr kinases that share a common
SQ/TQ substrate recognition motif [14, 15]. RASSF1A
possesses a single SQ motif at Ser131 that is evolutionarily
conserved among RASSF1A homologs but absent from
related family members whose expression is less frequently
altered in tumors [1] (Figure 2A). After exposure to ionizing
radiation, endogenous RASSF1A reacted to a generic phos-
pho-SQ/TQ antibody (Figure S2A) and a specific antibody
raised against a phospho-Ser131 peptide containing residues
126–137 of RASSF1A (Figure 2B). Mutation of the SQ site abol-
ishes reactivity toward the phospho-specific antibody, and
phospho-RASSF1A is no longer detected (Figure 2B). Simi-
larly, phosphorylation was removed by pretreatment with the
PIKK inhibitor caffeine or lambda protein phosphatase
(Figures S2A and S2B). This is in agreement with previous
observations that suggested that the SQ site on a RASSF1A
peptide may be a substrate for the PIKK family [14, 15].
To verify that the phosphorylation of Ser131 is required for
DNA damage-dependent activation of MST2, we tested the
ability of RASSF1A-S131A to enhance MST2 kinase activity
upon ionizing radiation. Figure 2C shows that an inability to
phosphorylate S131 correlates with decreased MST2 associa-
tion and lower kinase activity. Taken together, these data sug-
gest that DNA damage-induced phosphorylation of RASSF1A-
Ser131 promotes MST2 binding to RASSF1A and is required




Figure 1. DNA Damage Activates the RASSF1A/
MST2 Signaling Pathway
(A) Endogenous MST2 was immunoprecipitated
from U2OS cells irradiated (10 Gy) and harvested
at the indicated time points. Immunoprecipitates
and lysates were probed with the indicated anti-
bodies.
(B) MCF7 cells were transfected with pcDNA3 or
FLAG-RASSF1A. Endogenous MST2 was immu-
noprecipitated 30 min after irradiation (10 Gy).
Immunoprecipitates and lysates were probed
with the indicated antibodies.
(C) HeLa cells transfected with small interfering
RNA (siRNA) against RASSF1A or a nontargeting
control were irradiated (4 Gy) and harvested at
the indicated time points. Endogenous MST2
was immunoprecipitated, and MST2 activity in
immunoprecipitates was determined via in gel
kinase assay.
(D) HeLa cells transfected with two different
siRNAs against RASSF1A, MST2, LATS1, or
a nontargeting control were seeded at 400 cells
per 6 cm dish. Results are representative of two
independent siRNAs for each target; siRNAs
ablated protein levels in HeLa cells as described
previously [7]. Cells were exposed to g-irradia-
tion (2 Gy), and surviving colonies were counted
14 days postirradiation. Error bars represent
standard error.
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To determine the kinase responsible for Ser131 phosphoryla-
tion in response to DNA damage, we pretreated MCF7 cells
transfected with RASSF1A with either LY94002 (a pan PIKK
inhibitor), KU55933 (a specific ATM inhibitor that, at 10 mM,
does not inhibit ATR; Calbiochem), or Nu7026 (a DNA-PKcs
inhibitor). Only those cells treated with LY94002 and the ATM
inhibitor KU55933 showed reduced phosphorylation of Ser131
in response to DNA damage (Figure S3A). Furthermore, exog-
enous FLAG-RASSF1A was detected in immunoprecipitates of
ATM but not DNA-PKcs (Figure S3B). The lack of an effect seen
with Nu7026 on the phosphorylation of RASSF1A-Ser131
combined with the failure of RASSF1A and DNA-PKcs to
associate by immunoprecipitation implies that ATM, and not
DNA-PKcs, phosphorylates RASSF1A in response to ionizing
radiation.
To strengthen the hypothesis that ATM is the kinase
responsible for phosphorylation of Ser131, we examined the
phospho-RASSF1A status in ATM-deficient (pEBS) and ATM-
complemented (YZ3) cells [16], which express ATM to
a comparable level of both HeLa and MCF7 cells (Figure S3C).
DNA damage failed to induce phosphorylation of RASSF1A in
pEBS cells, whereas RASSF1A was efficiently phosphorylated
in YZ3 cells (ATM+) in a DNA damage-dependent manner (Fig-
ure 3A). RASSF1A-S131A was not phosphorylated in either
pEBS or YZ3 (Figure 3A), suggesting that RASSF1A-Ser131
is phosphorylated in an ATM and DNA damage-dependent
manner.
Next we sought to confirm that ATM directly phosphorylates
RASSF1A in an in vitro kinase assay. HA-RASSF1A or HA-R-
ASSF1A-S131A immunopurified from MCF7 cells was incu-
bated with FLAG-ATM or controls from irradiated and nonirra-
diated cells. A specific band corresponding to phosphorylated
RASSF1A was only detected when HA-RASSF1A was incu-
bated with ATM and was more pronounced upon activation
by ionizing radiation (Figure 3B); similar results were observed
when cisplatin was used to activate ATM (data not shown).Taken together, these data strongly argue that the RASSF1A
protein is a specific and direct substrate for ATM. To verify
that endogenous RASSF1A is phosphorylated, we immuno-
precipitated RASSF1A from HeLa cells and probed with both
the phospho-SQ/TQ generic substrate and the specific phos-
pho-Ser131 antibodies. Figure 3C and Figure S2A show a time-
dependent increase in phosphorylation of RASSF1A-Ser131,
with initial phosphorylation detected 15–30 min post ionizing
radiation, correlating with the association of ATM (Figure 3C).
The interaction of endogenous RASSF1A and ATM induced by
DNA damage in HeLa cells was also visualized as increased
levels of FLAG-RASSF1A in ATM immunoprecipitates from
irradiated U2OS cells (Figure S3B). To investigate the mecha-
nism of how ATM phosphorylation may activate MST2, we first
determined whether activation of RASSF1A itself could be
observed as previously described [17]. Cotransfection of
HA-RASSF1A and FLAG-RASSF1A indicated a degree of
dimerization that was enhanced by DNA damage (Figure 3D;
Figure S3D). Moreover, mutation of the Ser131 site or inhibition
of ATM destroyed the DNA damage-mediated dimerization of
RASSF1A (Figure 3D), suggesting that failure to dimerize
results in a failure to activate MST2 kinase activity
(Figure 2C). N-terminal RASSF1A residues have been previ-
ously reported to promote self-association independent of
the Salvador, RASSF1A, and Hippo (SARAH) domain [17].
Therefore, the enhanced association of MST2 with dimerized
and Ser131-phosphorylated RASSF1A (Figure 2C; Figure 3D)
may be due to an orientation of the RASSF1A SARAH domains,
which have a higher affinity for MST2 than the monomer.
Because ATM is relaying signals detected from the sensing
of DNA damage to RASSF1A, we predicted that inhibition of
ATM should prevent activation of the kinases downstream of
RASSF1A. Indeed, the association of MST2 and LATS1 was
impeded either by mutation of the ATM site or by inhibition
of ATM (Figure S3E). In contrast, MST2 association with
LATS1 was not affected by pretreatment with the DNA-PKcs
inhibitor Nu7026 (data not shown). This implies that inhibition
AB
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Figure 2. RASSF1A Is Phosphorylated at Ser131 following Ionizing
Radiation
(A) Alignment of a conserved SQ motif in RASSF1A sequences from verte-
brates; the matching sequence in RASSF5 is included for comparison.
Mutations that have been identified in human lung and ovarian cancer cells
[8, 19] in proximity to Ser131 are highlighted in bold.
(B) MCF7 cells were transfected with pcDNA3 or plasmid expressing FLAG-
RASSF1A or S131A-mutated FLAG-RASSF1A. Cells were harvested 30 min
post g-irradiation (10 Gy). FLAG-tagged proteins were immunoprecipitated
and probed by western blot with the phosphospecific antibody raised
against a phospho-Ser131 peptide spanning residues 125–136 of RASSF1A.
Lysates and immunoprecipitates were blotted with the indicated antibodies.
The data shown are representative of three independent experiments.
Phospho-Ser131 bands were normalized to the loading controls, and bands
were quantitated with ImageJ software. Error bars represent standard error.
(C) MCF7 cells were transfected with either pcDNA3 or plasmid expressing
FLAG-RASSF1A or S131A-mutated FLAG-RASSF1A. Cells were irradiated
(10 Gy) and harvested 30 min following irradiation. Endogenous MST2
was immunoprecipitated and probed by western blot for anti-MST2
and anti-FLAG. The kinase activity of MST2 in immunoprecipitates was
determined by in gel kinase assay. Lysates were probed with indicated
antibodies.
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2022of ATM restricts not only RASSF1A phosphorylation but
also the ability of MST2 and LATS1 to associate upon DNA
damage.
Mutation of RASSF1A-Ser131 Blocks the Response
to DNA Damage
In order to address whether the phosphorylation of RASSF1A-
Ser131 has physiological significance, we addressed the
ability of MCF7 cells to form colonies after exposure to
ionizing radiation. In agreement with Figure 1D, Figure 4A
(left) shows a reduction in the ability of RASSF1A-expressing
cells to form colonies following ionizing radiation, whereas
RASSF1A-S131A-expressing cells are equivalent to controls.
In addition, similar results were observed when RASSF1A-
and RASSF1A-S131A-expressing cells were tested for
viability in a resazurin assay post DNA damage (Figure 4A,
right), indicating that RASSF1A has an important tumor-
suppressor role in the DNA damage response. Because
methylation of RASSF1 appears to affect sensitivity of tumors
to both chemo- and radiotherapy, we examined whether
RASSF1A could exacerbate DNA damage-induced apoptosis
from additional DSB-inducing agents. Exogenous expression
of RASSF1A in U2OS cells enhanced the apoptotic response
to cisplatin, etoposide, and doxorubicin (Figure 4B, left), indi-
cating a role for RASSF1A in a general response to DNA-
damaging agents. The strongest enhancement of apoptosis
was seen with cisplatin, which has been previously shown
to engage p73 [18]. If this pathway is implicit in a DNA-damage
response, then ablation of pathway components should
restrict DNA damage-induced apoptosis. Figure 4B (right)
shows that RASSF1A depletion reduces cisplatin-induced
apoptosis in HeLa cells to a similar extent as observed
when p73 itself is depleted. As with RASSF1A, siRNA deple-
tion of MST2, LATS1, and YAP1 also reduced the apoptotic
response to cisplatin (Figure 4B, right). Therefore, we were
prompted to address whether the phosphorylation of
RASSF1A in response to DNA damage mediated the stabiliza-
tion of p73. As shown previously, expression of RASSF1A
enhances the stability of p73 [7], but this stabilization was
further enhanced when combined with DNA damage (Fig-
ure 4C, left). In agreement with a role for the ATM phosphory-
lation site in pathway signaling, RASSF1A-S131A blocked the
stabilization of p73 in response to cisplatin-mediated DNA
damage (Figure 4C, right). Similar results were observed for
YAP1 stabilization (Figure S4A) and a transcriptional target
of YAP1/p73, p21 (Figure S4B). Interestingly, loss of apoptotic
responsiveness (Figure 4B, right) following knockdown of
RASSF1A in HeLa cells correlated with the reduced stabiliza-
tion of p73 in response to cisplatin (Figure 4C, left), an effect
that may explain lower cisplatin sensitivity of tumors methyl-
ated for RASSF1A [5].
To address whether phosphorylation of RASSF1A-Ser131
has physiological tumor relevance, we took advantage of the
fact that RASSF1A variants harboring mutations in and near
the ATM site have been isolated from breast, ovarian, and
lung cancer patients [8, 19] (Figure 2A). Because one mutation
directly altered the Ser131 site to Phe (F), we addressed
whether this mutation affects MST2 activation in response to
DNA damage. As observed in Figure 1B for MST2-LATS1 asso-
ciation in MCF7 cells, low-level MST2 activity can be triggered
in response to DNA damage in the absence of exogenous
RASSF1A (Figure 4D, top). We interpret these effects to be
due to residual expression of RASSF1A because this activity




Figure 3. ATM Phosphorylates RASSF1A-Ser131 in Response to DNA Damage
(A) ATM null (pEBS) or ATM reconstituted (YZ3) cells were transfected with pcDNA3 or plasmid expressing FLAG-RASSF1A or S131A-mutated FLAG-
RASSF1A. Cells were harvested 30 min post g-irradiation (10 Gy). FLAG-tagged proteins were immunoprecipitated and probed by western blot with the
phosphospecific antibody raised against the phospho-Ser131 peptide. Data shown are representative of four independent experiments. Phospho-
Ser131 bands were normalized to the loading controls, and bands were quantitated with ImageJ software. Error bars represent standard error.
(B) In vitro kinase assay of immunoprecipitated FLAG-ATM from YZ5 cells [16] incubated with HA-RASSF1A immunopurified from MCF7 cells in the
presence of [g-32P]ATP. Reactions were resolved by SDS polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene fluoride
(PVDF) membrane. The membrane was visualized by phosphoimage detection (PMI imager, Bio-Rad) and probed with the indicated antibodies.
(C) HeLa cells were irradiated (10 Gy) and harvested at the indicated time points. Endogenous RASSF1A was immunoprecipitated, and immunoprecipitates
were probed by western blot with indicated antibodies.
(D) MCF7 cells were cotransfected with FLAG-RASSF1A and HA-RASSF1A (2.5 mg DNA each), FLAG-RASSF1A-S131A and HA-RASSF1A-S131A (2.5 mg
DNA each), or pcDNA3 (5 mg DNA). Cells were preincubated with 10 mM KU55399 (ATMi) or an equivalent volume of dimethyl sulfoxide (DMSO) before
irradiation (10 Gy). Cells were harvested 30 min following irradiation. FLAG-tagged proteins were immunoprecipitated and probed by western blot with
both anti-FLAG and anti-HA. Lysates were probed with indicated antibodies.
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2023Expression of exogenous RASSF1A at a level that does not
elicit maximal MST2 kinase activity allowed the observation
of a responsiveness to DSB signaling, and, importantly, muta-
tion of Ser131 to Phe ablated the response (Figure 4D, top). To
address whether mutations at the RASSF1A-Ser131 site in
tumors might represent an ‘‘escape mechanism’’ for tumor
cells in response to DNA damage, we addressed the relevance
of this event to colony survival. We again asked whether we
could sensitize RASSF1 methylated tumor cells to DNA
damage through reexpression of RASSF1A or tumor-derived
RASSF1A-S131F. Because RASSF1A has been reported to
stabilize p53 [20], we selected H1299 cells, which are p53
null tumor cells that are also methylated atRASSF1, thus ruling
out any contribution to colony survival from p53-associated
effects. As observed for ionizing radiation, Figure 4D (bottom)
shows that expression of RASSF1A reduced the colony-form-
ing ability of cells exposed to cisplatin treatment. Expression
of RASSF1A-S131F, however, failed to suppress colony
growth, indicating that the tumor cells from which this mutantoriginally derived are likely to have a defective DNA damage
response as a result of RASSF1A mutation. Ultimately, this
demonstrates that epigenetic loss or mutation of RASSF1A-
Ser131 leads to a reduced response to DNA damage and an
increased tumorigenic capacity.
Conclusions
The results described here present a novel role for RASSF1A
in responding to DNA damage. This role is dependent on the
phosphorylation of Ser131 by ATM and leads to p73 stabiliza-
tion and activation through the downstream kinases MST2
and LATS1. The RASSF1A pathway has been described to
affect DNA damage-dependent p53 stabilization [20–23];
however, p53 is commonly mutated or inactivated in the
majority of human tumors. Interestingly, p73 is rarely mutated
in human cancers [24], and the activation of this protein is
important for the removal of aberrantly proliferating cells
when p53 is absent [25]. The activation of p73 has been shown




Figure 4. RASSF1A Requires Phosphorylation of S131 to Signal to p73, Induce Apoptosis, and Suppress Colony Formation
(A) Left: MCF7 cells were transfected with either pcDNA3, FLAG-RASSF1A, or mutated FLAG-RASSF1A-S131A. Cells were seeded at 400 cells per 6 cm dish
and exposed to ionizing radiation (2 Gy). Surviving colonies were counted after 14 days. Right: H1299 cells were cultured with 15 mM cisplatin for 48 hr, and
cell viability was determined with the resazurin assay. Error bars represent standard error.
(B) Left: U2OS cells transfected with pcDNA3 or FLAG-RASSF1A were treated with DNA damage-inducing drugs cisplatin (25 mM), etoposide (10 mM),
or doxorubicin (10 mM) for 40 hr, and apoptotic cells were detected by examining caspase activity in fluorescence-activated cell sorting (FACS) assay.
*p < 0.05, **p < 0.05, ***p < 0.05. Right: HeLa cells transfected with siRNA against RASSF1A, MST2, LATS1, YAP1, p73, or a nontargeting control (NT)
were treated with 25 mM cisplatin for 24 hr, and apoptotic cells were detected by FACS. Results are representative of two independent siRNAs for each
target; siRNAs ablated protein levels in HeLa cells (here and in Figure 1D) as described previously [7]. Error bars represent standard error.
(C) Left: HeLa cells transfected with pcDNA3, FLAG-RASSF1A, or mutated FLAG-RASSF1A-S131A together with HA-P73 were treated with 25 mM cisplatin
for 16 hr. Lysates were blotted with the indicated antibodies. Right: HeLa cells transfected with siRNA against RASSF1A or a nontargeting control were
treated with 25 mM cisplatin for 24 hr. Lysates were probed with the indicated antibodies.
(D) Top: MCF7 cells were transfected with pcDNA3, FLAG-RASSF1A, or mutated FLAG-RASSF1A-S131F and treated as indicated with 10 mM etoposide.
Endogenous MST2 was immunoprecipitated, and activity was determined by in gel kinase assay. Lysates and immunoprecipitates were blotted with the
indicated antibodies. Bottom: H1299 cells transfected with pcDNA3, FLAG-RASSF1A, or mutated FLAG-RASSF1A-S131F were seeded at 400 cells per
6 cm dish. Cells were exposed to 25 mM cisplatin for 4 hr, and surviving colonies were counted after 14 days. Error bars represent standard error.
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status of the cell [25]. The stabilization of p73 and the tran-
scriptional coactivator YAP1 enhance the transcriptional
activity of p73 targets in response to DNA damage [26, 27],
and we show here that these events appear to require phos-
phorylation of RASSF1A-Ser131 (Figure 4C; Figures S4A and
S4B).
Our previous work demonstrated that RASSF1A can stabi-
lize p73 through regulation of YAP1 and promote apoptosis.
ATM phosphorylation of RASSF1A is likely to act concur-
rently with c-Abl-mediated signaling [28] to stabilize a
YAP1/p73 complex to coordinate p73 tumor suppression in
response to DNA damage. Song et al. [20] recently showed
that, in response to DNA damage, RASSF1A promotes the
disruption of the MDM2-DAXX-HAUSP complex, which
results in MDM2 self-ubiquitination, p53 stabilization, andsubsequent G1/S cell-cycle arrest. Taken together, the regu-
lation of both p53 and p73 implies that RASSF1A may have a
dual role in the coordination of p53 and p73 responses. p53 is
regulated by a number of additional pathways in response to
DNA damage that would make a p53 response less sensitive
to RASSF1A loss. However, in tumors where p53 is mutated
or deleted, it is p73 that is important for a response to
DNA damage. This may provide an explanation as to why
tumors that have lost RASSF1A expression (via promoter
methylation), and hence the capacity to stabilize p73,
appear to have increased resistance to chemo- and radio-
therapy [6]. Therefore, understanding the mutational status
of the ATM site in RASSF1A in nonmethylated RASSF1
tumors is likely to be a significant factor in predicting either
a response to therapy or correlation with DNA repair-deficient
phenotypes [29].
ATM and RASSF1A Regulate a p73 DNA Damage Response
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